- Approval Id
- c8d8923c7e7727f0
- Drug Approval Emc Name
- Pethidine 50mg/ml & 100mg/2ml Solution for Injection
- Drug Name
- Pethidine 50mg/ml & 100mg/2ml Solution for Injection
- Company Name
- Martindale Pharma, an Ethypharm Group Company
- Company Address
- Jupiter House, Mercury Park, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, UK
- Company Website
- http://ethypharm.co.uk/
- Company Telephone
- +44 (0) 1277 266 600
- Company Medical Info Email
- medinfo@ethypharm.com
- Atc Code
- N02AB
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Macarthys Laboratories Limited
T/A Martindale Pharma
Bampton Road,
Harold Hill,
Romford\*\*,\*\*
Essex\*\*,\*\*
RM3 8UG
UK.
- Authorisation Number
- PL 01883/6150R
- Authorisation Date
- Date of first authorisation:16/12/2008
- Instruction Authorisation Holder
- Macarthys Laboratories Limited
T/A Martindale Pharma
Bampton Road,
Harold Hill,
Romford\*\*,\*\*
Essex\*\*,\*\*
RM3 8UG
UK.
- Instruction Authorisation Number
- PL 01883/6150R
- Instruction Authorisation Date
- Date of first authorisation:16/12/2008
- Instruction Composition
- Pethidine Hydrochloride 5% w/v
(50mg in 1ml and 100mg in 2ml total volume)
For the full list of excipients, see section 6.1
- Instruction Dosage Form
- Solution for Injection
A clear colourless, particle free solution
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Relief of moderate to severe pain.
Premedication.
Obstetric analgesia.
Enhancement of analgesia4.2 Posology and method of administration
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with pethidine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4)
Posology
\*Adults\*.
\*For moderate or severe pain.\*
Normal single dose (usually not to be repeated more often than 4 hourly) By intramuscular or subcutaneous injection 25 - 100 mg.
By slow intravenous injection 25 - 50 mg.
\*For obstetric analgesia.\*
By intramuscular or subcutaneous injection repeated 1 - 3 hours later. 50 - 100 mg.
Maximum of 400mg in 24 hours.
\*As a premedication.\*
By intramuscular injection one hour prior to the operation. 50 - 100mg
\*For the enhancement of analgesia.\*
By slow intravenous injection. 10 - 25mg as required.
\*Elderly or debilitated patients.\*
Initial doses should not exceed 25mg as this group of patients may be specially sensitive to the central depressant effect of the drug.
Paediatric population
\*For moderate or severe pain.\*
By intramuscular injection. 0.5 - 2 mg per Kg of body weight.
\*As a premedication.\*
By intramuscular injection one hour prior to the operation. 1 - 2 mg per kg of body weight.
\*\*Method of administration\*\*
Intramuscular, intravenous or subcutaneous injection4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
Severe respiratory depression, severe obstructive airways disease or acute asthma.
It should not be administered to patients with severe renal impairment or severe hepatic impairment.
Should be avoided in patients with acute alcoholism, delirium tremens, raised intracranial pressure or in those with convulsive states such as status epilepticus.
It should not be administered to patients receiving monoamine oxidase inhibitors (including moclobemide, and the monoamine B inhibitors selegiline and rasagiline) or within two weeks of their withdrawal.
Pethidine should not be administered to patients receiving ritonavir.
Use of pethidine should be avoided in patients with supraventricular tachycardia.
Use of pethidine in patients with phaechromocytoma may result in hypertensive crisis.
Use of pethidine should be avoided in patients with diabetic acidosis where there is danger of coma.
In comatose patients
In patients with a risk of paralytic ileus
In patients with head injuries.4.4 Special warnings and precautions for use
Pethidine is controlled under the Misuse of Drugs Act 1971 (Schedule 2).
Repeated use may result in dependence of the morphine type.
Pethidine should be used with caution in patients with acute or chronic airflow obstruction including asthma.
Pethidine should be used with caution or in reduced doses in patients with myasthenia gravis.
Pethidine should only be given with caution and in reduced doses to neonates, premature infants, patients who are elderly or debilitated or those with impaired hepatic or renal function. Renal impairment may result in accumulation of the potentially toxic metabolite norpethidine, particularly with repeat dosing All of these patient groups may experience increased or prolonged effects of the product.
Pethidine should be used with caution in patients with shock, hypothyroidism, adreno-corticol insufficiency and a history of convulsive disorders.
Although less spasmogenic than morphine, pethidine may precipitate spasm of the ureter or Sphincter of Oddi. Subsequently it should be used with caution in patients with prostatic hypertrophy and biliary tract disorders including those with pain secondary to gallbladder pathology.
Pethidine should be used with caution in patients with existing hypotension as it may reduce the blood pressure further.
In addition it should be avoided in patients with severe inflammatory bowel disease due to its effects on the gastrointestinal tract where it may precipitate toxic megacolon.
Pethidine has a slower elimination rate and a larger inter-subject variability in neonates and young infants compared to older children and adults, which may lead to dose related reactions such as respiratory depression. If pethidine use is contemplated in neonates or young infants (up to 12 months), any potential benefits of the drug need to be weighed against the relative risk to the patient.
\*Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs:\*
Concomitant use of pethidine and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe pethidine concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
\*\*Drug dependence, tolerance and potential for abuse\*\*
For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g., major depression).
Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.
A comprehensive patient history should be taken to document concomitant medications, including over the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance.
The risks of developing tolerance should be explained to the patient.
Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse, or addiction.
The clinical need for analgesic treatment should be reviewed regularly.
\*\*Drug withdrawal syndrome\*\*
Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with pethidine.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
\*\*Hyperalgesia\*\*
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain.
This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.4.5 Interaction with other medicinal products and other forms of interaction
\*Monoamine Oxidase Inhibitors\*
The concurrent use of MAOIs (including moclobemide) is contra-indicated (see section 4.3) as they may result in CNS excitation or depression.
Pethidine should not be administered to patients receiving monoamine oxidase inhibitors or moclobemide or within two weeks of their withdrawal (see Section 4.3).
\*CNS depressants\*
CNS depressants such as alcohol, hypnotics, anxiolytics and sedatives, barbiturates and tricyclic antidepressants may increase the general depressant effects of pethidine and should therefore be used with caution.
\*Opioid agonists\*
Additive effects on CNS depression, respiratory depression and hypotension can occur with concomitant use of opioid agonist analgesics.
\*MAO-B inhibitors\*
Concomitant use of MAO-B inhibitors such as selegiline or rasagiline is contraindicated (see section 4.3) as this may lead to hyperpyrexia and CNS toxicity.
Rasagiline should not be given with pethidine as there is risk of CNS toxicity, its use should be avoided for two weeks after taking rasagiline.
\*Anticonvulsants\*
Administration of phenytoin may cause an increase in hepatic metabolism of pethidine and subsequently increased levels of norpethidine (a toxic metabolite).
\*Antipsychotics\*
Concomitant use of phenothiazines and pethidine can induce severe hypotension.
\*Anti-virals\*
Plasma concentrations of pethidine may be decreased by concomitant administration of ritonavir, however levels of norpethidine (a toxic metabolite) may rise. Concomitant administration of ritonavir and pethidine should be avoided (see section 4.3).
\*Histamine H2 antagonists\*
Cimetidine can reduce the metabolism of pethidine resulting in increased plasma concentration.
\*Effects of pethidine on other drugs\*
Pethidine may have an effect on the activities of other drugs, for example domperidone, as a consequence of reduced gastro-intestinal motility.
The plasma levels of ciprofloxacin may be reduced in the presence of opiate premedicants.
Plasma levels of mexiletine may also be reduced in the presence of opioid analgesics.
Possible increased serotonergic effects when pethidine is given with SSRI's.
\*Sedative medicines such as benzodiazepines or related drugs:\*
The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
There is inadequate evidence of safety in human pregnancy, but the drug has been in widely use for many years without apparent ill consequence. Animal studies have not shown any hazard.
As with all drugs during pregnancy care should be taken in assessing the risk to benefit ratio.
Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.
If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.
\*\*Breast feeding\*\*
Administration to nursing women is not recommended as pethidine may be secreted in breast milk and may cause respiratory depression in the infant.4.7 Effects on ability to drive and use machines
Patients should not drive or use machines while taking pethidine as it may cause drowsiness and reduce alertness.
The ability to drive or use machines may be severely affected during and for some time after administration of pethidine. This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called 'statutory defence') if:
| | |
| --- | --- |
| | o The medicine has been prescribed to treat a medical or dental problem and o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and o It was not affecting your ability to drive safely |4.8 Undesirable effects
There are no modern clinical studies available that can be used to determine the frequency of undesirable effects. Therefore, all the undesirable effects listed are classified as “frequency unknown” (cannot be estimated from the available data).
The undesirable effects listed below include class effects for opioid analgesics and effects related to the pharmacologically active metabolite, norpethidine.
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Frequency\*\* | \*\*Adverse Event\*\* |
| \*Immune system disorders\* | Unknown | General hypersensitivity reactions |
| \*Psychiatric disorders\* | Unknown | Drug Dependence (see section 4.4), confusion, mood altered, mild euphoria, hallucinations, dysphoria |
| \*Nervous system disorders\* | Unknown | Drowsiness, dizziness, tremor, convulsions, headache, fainting, CNS excitation |
| \*Eye disorders\* | Unknown | Dry eye, miosis, corneal reflex decreased |
| \*Ear and labyrinth disorders\* | Unknown | Vertigo |
| \*Cardiac disorders\* | Unknown | Tachycardia, bradycardia, palpitations |
| \*Vascular disorders\* | Unknown | Orthostatic hypotension, flushing, hypotension, hypertension, vasodilation |
| \*Respiratory, thoracic and mediastinal disorders\* | Unknown | Respiratory depression |
| \*Gastrointestinal disorders\* | Unknown | Nausea, vomiting, dry mouth, constipation |
| \*Hepatobiliary disorders\* | Unknown | Biliary or Ureteric spasm |
| \*Skin & subcutaneous tissue disorders\* | Unknown | Sweating, rash, urticaria, pruritus |
| \*Musculoskeletal and connective tissue disorders\* | Unknown | Muscle twitching |
| \*Renal & urinary disorders\* | Unknown | Difficulty in micturition, renal colic |
| \*Reproductive system and breast disorders\* | Unknown | Sexual dysfunction |
| \*General disorders & administration site conditions\* | Unknown Uncommon | Hypothermia, weakness, injection site reactions including induration and irritation drug withdrawal syndrome |
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
\*Symptoms\*
Respiratory depression, CNS depression with extreme somnolence progressing to incoordination, stupor or coma, convulsions, CNS stimulation, cyanosis, miosis, skeletal muscle flaccidity or tremors, cold, clammy skin, hypothermia, bradycardia and hypotension.
In severe overdosage, apnoea, circulatory collapse, pulmonary oedema, mydriasis, cardiac arrest and death may occur.
\*Management\*
Treatment is supportive. A patent airway must be established with assisted or controlled ventilation. If signs of CNS toxicity are exhibited the use of pethidine should be discontinued. Narcotic antagonists may be required if there is evidence of significant respiratory or cardiovascular depression.
Naloxone should be given intravenously as soon as possible and repeated every 2-3 minutes if necessary (refer to naloxone product literature for details).
Anti-convulsive therapy, oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Analgesics – Phenylpiperidine derivatives.
ATC code: NO2A B.
Pethidine is a synthetic opioid analgesic similar to morphine although less potent and shorter acting. Its analgesic effect usually lasts for 2 to 4 hours. The analgesic effect occurs after about 10 minutes following parenteral administration. It acts on the CNS system and smooth muscles via the peripheral nervous system. However, it has a weaker action on smooth muscle than morphine and therefore has less effect on cough, bowel motility, biliary tone and secretion of pituitary hormones.
Pethidine also causes the release of histamine from mast cells resulting in a number of allergic-type reactions.
Pethidine is a narcotic analgesic with similar actions to morphine.5.2 Pharmacokinetic properties
Pethidine is rapidly absorbed following intramuscular or subcutaneous injection, however, there are wide inter-individual variations. It is widely distributed in the tissues with a volume of distribution of 200-300 litres and is extensively protein bound (60-80%).
Pethidine is metabolised in the liver and excreted via the urine (70% in 24 hours). One of the metabolites, norpethidine, is pharmacologically active and its accumulation can result in toxicity. Urinary excretion is pH-dependent, the lower the pH the greater the clearance. At normal urinary pH only a small amount of pethidine is excreted unchanged.
Pethidine has a plasma elimination half-life of about 3 to 6 hours. The metabolite norpethidine is eliminated more slowly with a half-life of up to 20 hours and may accumulate with chronic use, especially in the presence of renal impairment.
Pethidine crosses the placenta and is excreted in breast milk.
Both pethidine and norpethidine cross the blood/brain barrier and are found in the cerebrospinal fluid.
\*Paediatric population\*
A single study of pethidine pharmacokinetics1 was conducted in 21 infant patients who received a single 1mg/kg dose following surgery or during mechanical ventilation. Vc, Vss and t1/2 was shown to vary greatly between infant subjects, but were not demonstrated to correlate with age, gestational age, postconceptional age, weight or body surface area. Clearance was demonstrated to correlate with age, gestational age, postconceptional age, weight and body surface area. Median elimination half-life was demonstrated to be 10.7 hours (range 3.3. to 59.4 hours), median clearance was 8.0 ml/kg/min (range 1.8 to 34.9 ml/kg/min), median volume of the central compartment 2.4 L/kg (range 0.5 to 4.8 L/kg) and median steady-state volume of distribution was 7.2 L/kg (range 3.3 to 11.0 L/kg).
1 Pokela ML, Olkkola KT, Koivisto M, Ryhanen P. Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants. Clin Pharmacol Ther 1992;52(4):342-95.3 Preclinical safety data
No additional pre-clinical data of relevance to the prescriber.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Sodium Hydroxide may be added to adjust the pH.
Water for Injection6.2 Incompatibilities
In the absence of incompatibility studies, Pethidine must not be mixed with other medicinal products.
Pethidine is incompatible with barbiturate salts and with other drugs including aminophylline, heparin sodium, methicillin sodium, morphine sulphate, nitrofurantoin sodium, phenytoin sodium, sulphadiazine sodium, sodium iodide, sulphafurazole diethanolamine. Incompatibility has also been observed between pethidine hydrochloride and acyclovir sodium, imipenem, frusemide and idarubicin.
Colour changes or precipitation have been observed on mixing pethidine with the following drugs, minocycline hydrochloride, tetracycline hydrochloride, cefoperazone sodium, mezlocillin sodium, nafcillin sodium and liposomal doxorubicin hydrochloride.6.3 Shelf life
36 months.6.4 Special precautions for storage
Store below 25°C.
Keep the ampoules in the outer carton.
Protect from light.6.5 Nature and contents of container
1ml and 2ml in colourless Type 1 neutral glass ampoules. Fusion sealed. Packed in cartons of 10 ampoules.6.6 Special precautions for disposal and other handling
Pethidine is controlled under the Misuse of Drugs Act 1971 (Schedule 2).
- Instruction Content
- ## Composition
Pethidine Hydrochloride 5% w/v
(50mg in 1ml and 100mg in 2ml total volume)
For the full list of excipients, see section 6.1
## Pharmaceutical Form
Solution for Injection
A clear colourless, particle free solution
## Clinical Particulars
4.1 Therapeutic indications
Relief of moderate to severe pain.
Premedication.
Obstetric analgesia.
Enhancement of analgesia4.2 Posology and method of administration
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with pethidine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4)
Posology
\*Adults\*.
\*For moderate or severe pain.\*
Normal single dose (usually not to be repeated more often than 4 hourly) By intramuscular or subcutaneous injection 25 - 100 mg.
By slow intravenous injection 25 - 50 mg.
\*For obstetric analgesia.\*
By intramuscular or subcutaneous injection repeated 1 - 3 hours later. 50 - 100 mg.
Maximum of 400mg in 24 hours.
\*As a premedication.\*
By intramuscular injection one hour prior to the operation. 50 - 100mg
\*For the enhancement of analgesia.\*
By slow intravenous injection. 10 - 25mg as required.
\*Elderly or debilitated patients.\*
Initial doses should not exceed 25mg as this group of patients may be specially sensitive to the central depressant effect of the drug.
Paediatric population
\*For moderate or severe pain.\*
By intramuscular injection. 0.5 - 2 mg per Kg of body weight.
\*As a premedication.\*
By intramuscular injection one hour prior to the operation. 1 - 2 mg per kg of body weight.
\*\*Method of administration\*\*
Intramuscular, intravenous or subcutaneous injection4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
Severe respiratory depression, severe obstructive airways disease or acute asthma.
It should not be administered to patients with severe renal impairment or severe hepatic impairment.
Should be avoided in patients with acute alcoholism, delirium tremens, raised intracranial pressure or in those with convulsive states such as status epilepticus.
It should not be administered to patients receiving monoamine oxidase inhibitors (including moclobemide, and the monoamine B inhibitors selegiline and rasagiline) or within two weeks of their withdrawal.
Pethidine should not be administered to patients receiving ritonavir.
Use of pethidine should be avoided in patients with supraventricular tachycardia.
Use of pethidine in patients with phaechromocytoma may result in hypertensive crisis.
Use of pethidine should be avoided in patients with diabetic acidosis where there is danger of coma.
In comatose patients
In patients with a risk of paralytic ileus
In patients with head injuries.4.4 Special warnings and precautions for use
Pethidine is controlled under the Misuse of Drugs Act 1971 (Schedule 2).
Repeated use may result in dependence of the morphine type.
Pethidine should be used with caution in patients with acute or chronic airflow obstruction including asthma.
Pethidine should be used with caution or in reduced doses in patients with myasthenia gravis.
Pethidine should only be given with caution and in reduced doses to neonates, premature infants, patients who are elderly or debilitated or those with impaired hepatic or renal function. Renal impairment may result in accumulation of the potentially toxic metabolite norpethidine, particularly with repeat dosing All of these patient groups may experience increased or prolonged effects of the product.
Pethidine should be used with caution in patients with shock, hypothyroidism, adreno-corticol insufficiency and a history of convulsive disorders.
Although less spasmogenic than morphine, pethidine may precipitate spasm of the ureter or Sphincter of Oddi. Subsequently it should be used with caution in patients with prostatic hypertrophy and biliary tract disorders including those with pain secondary to gallbladder pathology.
Pethidine should be used with caution in patients with existing hypotension as it may reduce the blood pressure further.
In addition it should be avoided in patients with severe inflammatory bowel disease due to its effects on the gastrointestinal tract where it may precipitate toxic megacolon.
Pethidine has a slower elimination rate and a larger inter-subject variability in neonates and young infants compared to older children and adults, which may lead to dose related reactions such as respiratory depression. If pethidine use is contemplated in neonates or young infants (up to 12 months), any potential benefits of the drug need to be weighed against the relative risk to the patient.
\*Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs:\*
Concomitant use of pethidine and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe pethidine concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
\*\*Drug dependence, tolerance and potential for abuse\*\*
For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g., major depression).
Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.
A comprehensive patient history should be taken to document concomitant medications, including over the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance.
The risks of developing tolerance should be explained to the patient.
Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse, or addiction.
The clinical need for analgesic treatment should be reviewed regularly.
\*\*Drug withdrawal syndrome\*\*
Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with pethidine.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
\*\*Hyperalgesia\*\*
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain.
This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.4.5 Interaction with other medicinal products and other forms of interaction
\*Monoamine Oxidase Inhibitors\*
The concurrent use of MAOIs (including moclobemide) is contra-indicated (see section 4.3) as they may result in CNS excitation or depression.
Pethidine should not be administered to patients receiving monoamine oxidase inhibitors or moclobemide or within two weeks of their withdrawal (see Section 4.3).
\*CNS depressants\*
CNS depressants such as alcohol, hypnotics, anxiolytics and sedatives, barbiturates and tricyclic antidepressants may increase the general depressant effects of pethidine and should therefore be used with caution.
\*Opioid agonists\*
Additive effects on CNS depression, respiratory depression and hypotension can occur with concomitant use of opioid agonist analgesics.
\*MAO-B inhibitors\*
Concomitant use of MAO-B inhibitors such as selegiline or rasagiline is contraindicated (see section 4.3) as this may lead to hyperpyrexia and CNS toxicity.
Rasagiline should not be given with pethidine as there is risk of CNS toxicity, its use should be avoided for two weeks after taking rasagiline.
\*Anticonvulsants\*
Administration of phenytoin may cause an increase in hepatic metabolism of pethidine and subsequently increased levels of norpethidine (a toxic metabolite).
\*Antipsychotics\*
Concomitant use of phenothiazines and pethidine can induce severe hypotension.
\*Anti-virals\*
Plasma concentrations of pethidine may be decreased by concomitant administration of ritonavir, however levels of norpethidine (a toxic metabolite) may rise. Concomitant administration of ritonavir and pethidine should be avoided (see section 4.3).
\*Histamine H2 antagonists\*
Cimetidine can reduce the metabolism of pethidine resulting in increased plasma concentration.
\*Effects of pethidine on other drugs\*
Pethidine may have an effect on the activities of other drugs, for example domperidone, as a consequence of reduced gastro-intestinal motility.
The plasma levels of ciprofloxacin may be reduced in the presence of opiate premedicants.
Plasma levels of mexiletine may also be reduced in the presence of opioid analgesics.
Possible increased serotonergic effects when pethidine is given with SSRI's.
\*Sedative medicines such as benzodiazepines or related drugs:\*
The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
There is inadequate evidence of safety in human pregnancy, but the drug has been in widely use for many years without apparent ill consequence. Animal studies have not shown any hazard.
As with all drugs during pregnancy care should be taken in assessing the risk to benefit ratio.
Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.
If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.
\*\*Breast feeding\*\*
Administration to nursing women is not recommended as pethidine may be secreted in breast milk and may cause respiratory depression in the infant.4.7 Effects on ability to drive and use machines
Patients should not drive or use machines while taking pethidine as it may cause drowsiness and reduce alertness.
The ability to drive or use machines may be severely affected during and for some time after administration of pethidine. This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called 'statutory defence') if:
| | |
| --- | --- |
| | o The medicine has been prescribed to treat a medical or dental problem and o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and o It was not affecting your ability to drive safely |4.8 Undesirable effects
There are no modern clinical studies available that can be used to determine the frequency of undesirable effects. Therefore, all the undesirable effects listed are classified as “frequency unknown” (cannot be estimated from the available data).
The undesirable effects listed below include class effects for opioid analgesics and effects related to the pharmacologically active metabolite, norpethidine.
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Frequency\*\* | \*\*Adverse Event\*\* |
| \*Immune system disorders\* | Unknown | General hypersensitivity reactions |
| \*Psychiatric disorders\* | Unknown | Drug Dependence (see section 4.4), confusion, mood altered, mild euphoria, hallucinations, dysphoria |
| \*Nervous system disorders\* | Unknown | Drowsiness, dizziness, tremor, convulsions, headache, fainting, CNS excitation |
| \*Eye disorders\* | Unknown | Dry eye, miosis, corneal reflex decreased |
| \*Ear and labyrinth disorders\* | Unknown | Vertigo |
| \*Cardiac disorders\* | Unknown | Tachycardia, bradycardia, palpitations |
| \*Vascular disorders\* | Unknown | Orthostatic hypotension, flushing, hypotension, hypertension, vasodilation |
| \*Respiratory, thoracic and mediastinal disorders\* | Unknown | Respiratory depression |
| \*Gastrointestinal disorders\* | Unknown | Nausea, vomiting, dry mouth, constipation |
| \*Hepatobiliary disorders\* | Unknown | Biliary or Ureteric spasm |
| \*Skin & subcutaneous tissue disorders\* | Unknown | Sweating, rash, urticaria, pruritus |
| \*Musculoskeletal and connective tissue disorders\* | Unknown | Muscle twitching |
| \*Renal & urinary disorders\* | Unknown | Difficulty in micturition, renal colic |
| \*Reproductive system and breast disorders\* | Unknown | Sexual dysfunction |
| \*General disorders & administration site conditions\* | Unknown Uncommon | Hypothermia, weakness, injection site reactions including induration and irritation drug withdrawal syndrome |
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
\*Symptoms\*
Respiratory depression, CNS depression with extreme somnolence progressing to incoordination, stupor or coma, convulsions, CNS stimulation, cyanosis, miosis, skeletal muscle flaccidity or tremors, cold, clammy skin, hypothermia, bradycardia and hypotension.
In severe overdosage, apnoea, circulatory collapse, pulmonary oedema, mydriasis, cardiac arrest and death may occur.
\*Management\*
Treatment is supportive. A patent airway must be established with assisted or controlled ventilation. If signs of CNS toxicity are exhibited the use of pethidine should be discontinued. Narcotic antagonists may be required if there is evidence of significant respiratory or cardiovascular depression.
Naloxone should be given intravenously as soon as possible and repeated every 2-3 minutes if necessary (refer to naloxone product literature for details).
Anti-convulsive therapy, oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Analgesics – Phenylpiperidine derivatives.
ATC code: NO2A B.
Pethidine is a synthetic opioid analgesic similar to morphine although less potent and shorter acting. Its analgesic effect usually lasts for 2 to 4 hours. The analgesic effect occurs after about 10 minutes following parenteral administration. It acts on the CNS system and smooth muscles via the peripheral nervous system. However, it has a weaker action on smooth muscle than morphine and therefore has less effect on cough, bowel motility, biliary tone and secretion of pituitary hormones.
Pethidine also causes the release of histamine from mast cells resulting in a number of allergic-type reactions.
Pethidine is a narcotic analgesic with similar actions to morphine.5.2 Pharmacokinetic properties
Pethidine is rapidly absorbed following intramuscular or subcutaneous injection, however, there are wide inter-individual variations. It is widely distributed in the tissues with a volume of distribution of 200-300 litres and is extensively protein bound (60-80%).
Pethidine is metabolised in the liver and excreted via the urine (70% in 24 hours). One of the metabolites, norpethidine, is pharmacologically active and its accumulation can result in toxicity. Urinary excretion is pH-dependent, the lower the pH the greater the clearance. At normal urinary pH only a small amount of pethidine is excreted unchanged.
Pethidine has a plasma elimination half-life of about 3 to 6 hours. The metabolite norpethidine is eliminated more slowly with a half-life of up to 20 hours and may accumulate with chronic use, especially in the presence of renal impairment.
Pethidine crosses the placenta and is excreted in breast milk.
Both pethidine and norpethidine cross the blood/brain barrier and are found in the cerebrospinal fluid.
\*Paediatric population\*
A single study of pethidine pharmacokinetics1 was conducted in 21 infant patients who received a single 1mg/kg dose following surgery or during mechanical ventilation. Vc, Vss and t1/2 was shown to vary greatly between infant subjects, but were not demonstrated to correlate with age, gestational age, postconceptional age, weight or body surface area. Clearance was demonstrated to correlate with age, gestational age, postconceptional age, weight and body surface area. Median elimination half-life was demonstrated to be 10.7 hours (range 3.3. to 59.4 hours), median clearance was 8.0 ml/kg/min (range 1.8 to 34.9 ml/kg/min), median volume of the central compartment 2.4 L/kg (range 0.5 to 4.8 L/kg) and median steady-state volume of distribution was 7.2 L/kg (range 3.3 to 11.0 L/kg).
1 Pokela ML, Olkkola KT, Koivisto M, Ryhanen P. Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants. Clin Pharmacol Ther 1992;52(4):342-95.3 Preclinical safety data
No additional pre-clinical data of relevance to the prescriber.
## Pharmaceutical Particulars
6.1 List of excipients
Sodium Hydroxide may be added to adjust the pH.
Water for Injection6.2 Incompatibilities
In the absence of incompatibility studies, Pethidine must not be mixed with other medicinal products.
Pethidine is incompatible with barbiturate salts and with other drugs including aminophylline, heparin sodium, methicillin sodium, morphine sulphate, nitrofurantoin sodium, phenytoin sodium, sulphadiazine sodium, sodium iodide, sulphafurazole diethanolamine. Incompatibility has also been observed between pethidine hydrochloride and acyclovir sodium, imipenem, frusemide and idarubicin.
Colour changes or precipitation have been observed on mixing pethidine with the following drugs, minocycline hydrochloride, tetracycline hydrochloride, cefoperazone sodium, mezlocillin sodium, nafcillin sodium and liposomal doxorubicin hydrochloride.6.3 Shelf life
36 months.6.4 Special precautions for storage
Store below 25°C.
Keep the ampoules in the outer carton.
Protect from light.6.5 Nature and contents of container
1ml and 2ml in colourless Type 1 neutral glass ampoules. Fusion sealed. Packed in cartons of 10 ampoules.6.6 Special precautions for disposal and other handling
Pethidine is controlled under the Misuse of Drugs Act 1971 (Schedule 2).
